Rophylac Advertising Letter (correction)
This article was originally published in The Pink Sheet Daily
ZLB Behring received an "untitled" letter from the Center for Biologics Evaluation & Research dated Feb. 3 regarding promotional practices of its IGIV product Rophylac. In a Feb. 7 1article, "The Pink Sheet" DAILY inadvertently categorized it as a "warning" letter
You may also be interested in...
ZLB Behring is falsely promoting an unapproved indication for the immune globulin product in an American Hospital Formulary Service fact sheet, FDA says.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.